Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Allergan Japan Files TrenibotE for Glabellar Lines Treatment
November 26, 2025
- Taiho Begins Rolling US NDA Submission for Zipalertinib
November 26, 2025
- Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use
November 26, 2025
- Otsuka Files Novel ADHD Drug Centanafadine in US
November 26, 2025
- Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
November 26, 2025
- Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
November 25, 2025
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+
November 25, 2025
- Kyowa Kirin Begins Japan PIII Trial of Infigratinib for Achondroplasia
November 25, 2025
- Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
November 25, 2025
- Otsuka’s Hypercholesterolemia Med Nexletol Hits Japan Shelves
November 25, 2025
- Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit
November 21, 2025
- 60% of Japan Drug Makers See Lower Operating Profit in H1 FY2025, R&D Costs Weigh on Mid-Sized Firms
November 21, 2025
- ViiV Japan Pushing Digital Tools to Support Patient-Doctor Communication
November 21, 2025
- Japan OKs FoundationOne CDx for Augtyro’s NTRK Fusion Indication
November 21, 2025
- Kyowa Kirin Debuts Crysvita Prefilled Syringe and Lumicef Auto-Injector in Japan
November 20, 2025
- Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
- Nxera to No Longer Invest in Non-Priority Assets, Shifts 80% of Pipeline to Obesity and Metabolic Areas
November 19, 2025
- Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…